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List of abbreviations 
AVE - X-Score 1.2, mean of the HP, HM and HS scoring functions 
AVP - arginine vasopressin 
BIND - scoring function of AutoDock 3.05 
bRho - bovine rhodopsin 
BZD - benzodiazepine 
BZX - benzoxazinone 
dcpa - D-chlorophenylalanine 
digl - D-indanylglycine 
dpff - D-pentafluorophenylalanine 
dtrp - D-tryptophan 
d(oet)tyr - atosiban 
GPCR - G-protein-coupled receptors 
HP - X-Score 1.2, hydrophobic contact potential scoring function 
HM - X-Score 1.2, hydrophobic matching scoring function 
HS - X-Score 1.2, hydrophobic molecular surface scoring function 
Kj - inhibition constant 
MIF - molecular interaction field 
Mpa - p-mercaptopropionic acid 
MD - molecular dynamics 
OT - oxytocin 
Phe20rn8VT - Phe 20rn 8 vasotocin 
q2-GRS - cross-validated r2(q2)-guided region selection 
rate - 2R-2-amino-2-carboxy-l,2,3,4-tetrahydronaphthalene 
RMSD - root-mean-square distance 
rrmetcc- lR,3R-l,2,3,4-tetrahydro-l-methyl-P-carboline-3-carboxylic acid 
rtcc - 3R-l,2,3,4-tetrahydro-P-carboline-3-carboxylic acid 
S A - simulated annealing 
TM - transmembrane 
ViaR - vasopressin la receptor 
V2R - vasopressin 2 receptor 
AGbind - free energy of binding 
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I. Introduction 
At the recommendation of the WHO, preterm birth is defined as a gestational age less 
than 37 completed weeks of pregnancy or less than 259 days from the first day of the last 
menstrual period. Effective methods for the treatment of preterm labour have become major 
goals in modern obstetrics because preterm birth is the leading cause of infant morbidity and 
mortality. Today, the possible modes of treatment of preterm labour comprise 
P2-sympathimometics (fenoterol and hexoprenalin), MgSC>4 and NSAID (indomethacin, only 
used in the U.S.A.), which are associated with significant maternal and foetal side-effects. 
It is generally accepted that both oxytocin (OT) itself and the sensitivity of the uterus 
to OT play crucial roles in the initiation of both normal and pathologically early deliveries 
[Takahashi et al., 1980; Fuchs et al., 1982]. The application of OT antagonists is therefore a 
logical approach to prevent preterm labour. 
1.1. Structure and binding domains of the human oxytocin receptor (hOTR) 
Kimura et al. first isolated and identified the hOTR in 1992 [Kimura et al. ta b], 1992]. 
The receptor consists of 389 amino acids and belongs among class I (class A) receptors within 
the great family of G-protein-coupled receptors (GPCRs) [Gether, 2000]. After determination 
of the amino acid sequence of the hOTR, several research groups set out to determine the 
exact binding domain of peptide and non-peptide agonists and antagonists via 
receptor-binding techniques in truncated, chimaeric or point-mutated receptors. 
Early results were achieved by Mouillac et al. [1995]. The endogenous peptide ligand 
arginine vasopressin (AVP) was docked to the homology modelled rat vasopressin la receptor 
(V]aR) and the determined contact residues were selected for site-directed mutagenesis 
analysis. To determine the receptor-binding profile, peptide agonists and peptide and 
non-peptide antagonists were used. The changes in the affinities led to the following 
conclusions: Gin92, Gin96 and Gin119 are important residues in peptide agonist binding, but do 
not affect peptide or non-peptide antagonist binding; Lys116 and Gin'71 residues affect 
antagonist binding; cyclic neuropeptides are located in a pocket located in the first third of the 
transmembrane (TM) region of the receptor. The identified residues are highly conserved 
among the AVP and OT receptors; the same residues may be involved in agonist or antagonist 
binding in the hOTR. 
Postina et al. [ 1996] transferred the porcine OT receptor into the porcine vasopressin 2 
receptor (V2R) and, using peptide agonists and antagonist, identified the binding domains. 
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The peptide antagonist binding-domain is formed by TM helices 1, 2 and 7, with a major 
contribution to the binding affinity by the upper part of helix 7. In the peptide agonist binding, 
the following domains are included: the three extracellular (EC) loops (the second EC loop 
could interact with the cyclic part of the hormone), and the N-terminal domain (the first EC 
loop interacts with the C-terminal tripeptide part of OT). 
Using a vasotocin analogue (a cyclic peptide) with equivalent high affinity towards the 
hOTR and ViaR, Breton et al. [2001] identified 3 residues, LeuU4-Val115-Lys116 as the most 
important region of the TM3 domains of hOTR in peptide antagonist binding. They suggested 
that the binding domain of this vasotocin analogue could be similar in ViaR, due to the highly 
conserved regions in the TM2, 3, 6 and 7 domains. 
Using truncated and chimaeric hOTR (ViaRN-OTR), Hawtin et al. [2001] identified 
the terminal 12 residues in the N-terminal region, as a highly important part of the peptide 
agonist binding, which did not contribute to antagonist (peptide or non-peptide) binding. 
Later, this group [Wesley et al., 2002] successfully identified the Arg34 residue in the distal 
part of the N-terminal, which is also involved in the agonist binding. 
Gimpl et al. [2005] made an attempt to identify the binding domain of a newly 
synthetized peptide antagonist, barusiban [Nilsson et al., 2003], Barusiban exhibits several 
times higher affinity and potency for the hOTR than AVP or any other hOTR antagonist 
[Pierzynski et al., 2004]. They found an increased affinity of barusiban towards the chimaeric 
V2R when the TM1 and TM2 domains of hOTR were transferred to the V2R, although this 
increased affinity was much lower than that towards the hOTR. The effect of the 
Leu114-Val"5-Lys116 region of TM3 was also investigated, but they found no differences in 
the affinity towards the wild type and chimaeric V2R. 
There is so far only one literature report dealing with binding domain determination 
(experimentally and theoretically) of non-peptide OT antagonists containing the 
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benzoxazinone (BZX) structure. Hawtin et al. [2005] identified the Ala residue, which has 
a very important role in the high-affinity binding of BZX antagonists. Their work was based 
on the fact that L-371,257 binds with high affinity to the hOTR and rat OTR, but there is a 
3-fold difference in the binding of this compound as concerns its affinity towards the hViaR 
(Kd=3.7 nM) and the rat V[aR (K<j=3200 nM) [Williams et al., 1995]. Sequence alignment and 
comparison was performed for the TM7 segment of these receptors. The results revealed a 
high sequence homology (70%) of TM7, and it was noted that Ala (7.42 - Ballesteros 
numbering scheme) is present at positions 318, 317 and 342 in the hOTR, the rat OTR and the 
rat ViaR, respectively. In the human ViaR, a Gly (7.42) is present at position 337, which is 
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therefore a candidate for providing the contact required for the binding of L-371,257 and 
L-372,662. Further, theoretical calculations were performed: the hOTR was modelled by 
using the bovine rhodopsin (bRho) template, determined via X-ray studies by Palczewski et 
al. [2000], and the ligands were docked to the putative active site of the receptor. The docking 
evaluation resulted in the following conclusion: (1) Ala318 comes into hydrophobic contact 
with the non-peptide ligands, (2) Trp288 and Phe291 comes into 7i-stacking interactions with the 
central benzene ring, (3) the pyridine derivative is located in a hydrophobic pocket formed by 
lie49, Ala53, Val88 and Val93, and finally (4) the N-oxide part forms an H-bond with Ser322. 
1.2. Molecular modelling of hOTR - ligand complexes 
The first receptor-based OT antagonist modelling was reported by Gieldon et al. 
[2001]. YM087 [Tahara et al., 1997] was docked to the putative active site of the human Via, 
V2 and OTR models, with subsequent further minimization and molecular dynamics (MD) 
simulations. By evaluation of the interaction sites, the following residues were identified as 
elements responsible for the receptor - ligand interactions: Gin92, Val120, Met123, Thr127 and 
Ala318. 
Later, our own research group, using the same receptor model, identified the most 
likely active conformation formed between hOTR and 45 BZX analogues [Jojart et al., 2005]. 
The residues which formed the possible binding pocket were: Pro95, Val115, Gin"9, lie202, 
Phe284, Trp288, Phe3", Ser322 and Asn325. The anchor points defined by Hawtin et al. [2005] 
were determined in our complex: Trp288, Ser122 and later Ala318. This suggested that the 
receptor model used in the work could be suitable for the study of receptor - ligand 
interactions. Through the use of scoring functions and 3D-QSAR methods, the most likely 
active conformation was confirmed and models with predictive powers were developed. The 
major disadvantage of our model is that the hOTR was modelled by using a theoretical 
template [Pogozheva et al., 1998], and not the generally accepted bRho template. In the case 
of the 5-HT2B receptor, the bacteriorhodopsin template was a more relevant template [Manivet 
et al., 2002] than the bRho template, and in a study of oq¿-adrenergic receptor activation 
[Carrieri et al., 2001], the TM domains were packed by means of the Baldwin oc-carbon 
template [Baldwin et al., 1997]. 
The interactions between hOTR and peptide antagonists were also investigated. With 
the aid of molecular docking and dynamics (lipid bilayer and explicit water) calculations, the 
interactions of hOTR with atosiban and barusiban were explored. Comparison of the static 
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[Slusarz et al., 2003] and dynamic [Slusarz et al., 2004] anchor points demonstrated a great 
overlap. The residues involved in the atosiban binding were: Ala84, Asp85, Gin92, Gin96, 
Gin119, Met123, Ser126, Leu131, Ala181, Ala182, Asp186, Ala189, Leu216, Phe284, Met315, Ser319 and 
Asn . Docking and MD simulations of barusiban were also performed [Slusarz et al., 2005]. 
A quarter of the interaction sites were located in the TM1 and TM2 domains, with the 
remaining residues in the TM3-7 and EC2 loop. These results did not agree with the 
experimentally determined binding domain [Gimpl et al., 2005]. 
1.3. OT antagonists 
From a chemical aspect, the possible hOTR antagonists can be divided into groups: 
peptide and non-peptide compounds. 
The peptide atosiban [Tractocile®, [Mpa',D-Tyr(OEt)2,Thr4,Orn8]OT] is still in 
clinical use [Pharm J, 2000, 264:892]. As concerns the pharmacological characterization, the 
structure-activity relationship of the peptides may be summarized as follows: (1) the 
incorporation of Sar at position 7 leads to high antioxytocic and suppressed antidiuretic 
activities [Grzonka et al., 1983]; (2) peptides containing a basic amino acid (Arg or Om) at 
position 8 are more potent [Lebl, 1987]; (3) the amino acid at position 2 plays a key role in 
the antagonistic effect of the peptides: insertion of a D amino acid at position 2 results in 
enhanced antioxytocic properties, and the antagonist potency can be further increased by 
insertion of a bulky lipophilic amino acid at this position [Mellin et al., 1986; Flouret et al., 
1991]; (4) as neurohypophyseal hormones lacking an N-terminal amino group are inactivated 
quite slowly, most of the OT antagonists described to date contain Mpa (P-mercaptopropionic 
acid), Mca (P-mercapto-p,P-cyclopentamethylenepropionic acid) or Pen 
(P'-dimethylcysteine) instead of Cys at position 1 [Grzonka et al., 1991]. The major 
disadvantage of the peptide antagonists is that they can be administered only parenterally. 
The investigated non-peptide antagonists could also be divided into 2 groups: 
benzodiazepine (BZD) and benzoxazinone (BZX) derivatives. The tocolytic effect of 
sedatohypnotic BZXs (clonazepam, diazepam and nitrazepam) is related to the antagonist 
capacity on myometrial a-adrenergic receptors (Zupko et al., 2003). Since GW405212X 
(Figure la) is a potent and selective hOTR antagonist, but has a poor pharmacokinetic 
profile, structural modifications were performed at positions 1 and 3 [Wyatt et al., 2001]. 
a 
CI 
'NH 
31 yO 
H 
N O O 
Figure 1. The basic structures of non-peptide oxytocin antagonists: (a) GW405212X and (b) OPC21268. 
The BZX analogues were developed on the basis of results achieved at Otsuka 
[Yamamura et al., 1991]: OPC 21268 (Figure lb) has significant rat V|aR and V2R selectivity 
and oral activity. Further, Williams et al. [1995] demonstrated that OPC21268 is 60 times 
more selective towards the hOTR than the human ViaR. With the aid of structural 
modifications of this compound, several hundred new molecules were synthetized and 
pharmacologically characterized [Bell et al., 1998; Kuo et al., 1998; Williams et al., 1999; 
Wyatteftf/.[a-bl, 2002]. 
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II. Aims 
The aims of the study may be summarized as follows: 
(1) determination the influence of modified d-amino acid at position 2 on the structural 
elements of eight OT antagonists ([Mpa1 ,Xxx2 ,Gln4 ,Sar7, Arg8]OT) (Havass et al., 
2002; Table 1); 
(2) relevant 3D structure modelling of the hOTR; 
(3) docking studies of 58 non-peptide analogues containing the basic BZX structure, taken 
from the literature (Wyatt et al.1* b], 2002; Tables 2 and 3); 
(4) investigation of the quantitative structure-activity relationship by means of scoring 
functions and 3D-QSAR (CoMFA) methods. 
ID Structure KjiS.E.M (nM) 
d(oet)tyr 
dcp 
digl 
dpff 
dtrp 
rate 
rrmetcc 
rtcc 
HOOC 5.76±1.48 
9.00±2.00 
3.81±0.18 
52.90±20.5 
37.60±23.2 
1917.00±1682 
4700.00±745 
692.80±157 
Table 1. Structures and biological activities of the d-amino acids incorporated at position 2 in the 
[Mpa',Xxx2,Gln4,Sar7,Arg8]OT OT antagonists. Radioligand binding assays were performed on pregnant 
guinea-pig uterus membrane preparation, using [3H]OT [Havass el al., 2002], 
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Table 2. Structures and measured pKj values of the OT antagonists (training set). The receptor-binding studies were performed on the hOTR, with [ H]OT for displacement 
analysis. pKji negative logarithm of inhibition constant [Wyatt et a/.|a*b|, 2002]. 
ID R pKj ID R pK; ID R pK, ID R pK, 
Table 2. continued Structures and measured pKj values of the OT antagonists (training set). The receptor-binding studies were performed on the hOTR, using [3H]OT for 
displacement analysis. pK|: negative logarithm of inhibition constant.* Compounds 44 and 45 were included only in scoring calculations [Wyatt et a l b | , 2002]. 
ID R pK; ID R pKj ID R pKj ID R pK, 
Table 3. Structures and measured pKj values of the OT antagonists (test set). The receptor-binding studies were performed on the hOTR, using [3H]OT for displacement analysis. 
pK^ negative logarithm of inhibition constant [Wyatt et al.1*" 2002]. 
III. Materials and Methods 
111.1. Conformational analysis of peptide OT antagonists 
To explore the structural features of the investigated peptides (Table 1), we performed 
restrained (co dihedral angle) simulated annealing (SA). The protocol was as follows: (1) 2000 
structures were generated at high temperature (900 K); (2) the structures were minimized 
(grad=l) in order to avoid strained structures; (3) after the minimization, the structures were 
heated to 1000 K (10 ps), equilibrated at 1000 K (20 ps), and cooled down to 50 K (15 ps). 
After cooling, a final minimization was performed with the help of the steepest descent, the 
conjugated gradient and finally the truncated Newton methods in a consecutive manner; the 
gradients were 100, 10 and 0.001, respectively. The MMFF94s force field [Halgren[a'b,c'd], 
1996; Halgren et al., 1996] was utilized with a distance-dependent dielectric function (er=4r) 
and no cut-off for the long-range non-bonding interactions. During the dynamic phase, the 
dihedral angles were restrained in the trans conformation. The calculations were carried out 
with the Molecular Operating Environment 2005.06 [MOE 2005.06] software package. 
111.2. Receptor-based QSAR studies of non-peptide OT antagonists 
III.2.1. Homology modelling of the hOTR 
The homology modelling was performed by means of the homology modelling 
module of the MOE 2004.03 program package, using bRho as template (PDB accession 
number: 1F88.A). After the sequence alignment, which was taken from the literature [Hawtin 
et al., 2005], 100 structures were generated, and the average structure was selected for further 
refinement. The final model consisted of 322 amino acids, because 12 residues were taken 
into consideration from the N-terminal (Arg27-Leu38), and 16 from the C-terminal 
(Leu333-Ser348). The structure was minimized with the help of the steepest descent, the 
conjugated gradient and finally the truncated Newton methods in a consecutive manner; the 
gradients were 100, 10 and 0.001, respectively; the Amber94 force field [Cornell et al., 1995] 
was used with MOE 2004.03. 
After the minimization, the minimized structure was further refined with SA, using the 
AMBER8 [Case et al., 2004] program package. The SA protocol was as follows: the structure 
was heated to 600 K in 8 ps, equilibrated at 600 K for 20 ps, and cooled down to 50 K in 
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10 ps; the structure obtained was minimized (10000 cycles). During the protocol, the aC of 
the whole protein was restrained to the initial position with a force constant of 
150 kcal/molA2. Temperature coupling constants of 0.5, 1 and 0.5 ps were utilized in the 
heating, equilibration and cooling stage, respectively, and bonds involving H atoms were also 
constrained, using the SHAKE algorithm. During the calculations, a distance-dependent 
dielectric constant (sr=4) and a 30 A cut-off were utilized for the long-range non-bonded 
interactions. This cycle was repeated 50 times, and the structure with the lowest energy was 
subjected to docking calculation. 
III.2.2. Docking studies of the most active BZX analogue 
The docking study of the most active analogue [Table 2, compound 35] was carried out with 
AutoDock 3.05 program package (Figure 2) [Morris et al., 1998]. 
Figure 2. Structure of the docked compound. Red bonds were flexible during the docking calculation. The atoms 
denoted by a, b and c are those, which were used in the reorientation (a, b, c and c, b, a) procedure during the 
RESP calculation. 
Since the program allows only one of the docking partners to be flexible, the receptor 
was kept rigid, and translation (0.5 A / s t e p ) , rotation (5°/step) and quaternion (5°/step) 
movements were allowed for the ligand. The docking box was centred on the putative active 
site (52x60x78 grid points, 0.375 A grid point distance). In the calculation of the electrostatic 
grid map, the distance-dependent dielectric constant of Mehler and Solmayer was utilized 
[Mehler et al., 1991]. Lennard-Jones parameters 12-10 and 12-6 were used to model H-bonds 
and van der Waals interactions, respectively. During the docking calculation, the Lamarckian 
Genetic Algorithm with the pseudo-Solis and Wets method was used, with 250 individuals in 
the population. The stopping criterion was defined by the total number of energy evaluations, 
which was set to 5xl07. In one docking calculation, 50 structures were generated; this was 
repeated 10 times, which finally resulted in 500 structures. To determine possible initial active 
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conformations, the following filters were applied: (1) the estimated free energy of binding 
(AGbind) should be less than 1000 kcal/mol; (2) the distance between C21 and 07 (Figure 2) 
should be more than 15 A [extended conformation of the ligand; Hawtin et al., 2005; Jojart et 
al., 2005]; and (3) the presence of Ala318 as hydrophobic interaction point. On use of these 
filters, the number of possible complexes was decreased to 18. 
The high AGbind values (AGbind>0 kcal/mol) indicate that the evolved structures are 
crude, because the flexibility of the receptor was not allowed during the docking procedure, 
and therefore the possible binding pocket could not act on the ligand and vica versa (induced 
fit effect). Accordingly we performed further refinement calculations with restrained SA on 
the 18 complexes. 
The 18 complexes were refined with AMBER8, with the same SA protocol as 
described earlier. For the receptor the Amber94 [Cornell et al., 1995], and for the ligand the 
GAFF [Wang et al., 2004] force field was applied. The ligand RESP charge fitting was 
carried out with the RED-vII program package [Zaffran et al., 2005], using the Gaussian03 
quantum chemical program [Frisch et al., 2003]. From among the docked structures, 3 were 
selected at random and the reorientation was based on 3 atoms (Figure 2). 
After the SA protocol, with analysis of the 6 lowest-energy complexes, the final 
number of possible active conformation complexes was decreased to 3, and these were 
subjected to the MD simulation, which was performed by using the AMBER8 program suite. 
For the protein and the ligand, the Amber94 and GAFF force fields were utilized, 
respectively. The system was heated in a multi-step heating protocol: the temperature was 
increased from 0 K to 300 K in 5 steps (AT=60 K, At=10 ps); the time step was set to 0.5 fs. 
After the heating, the system was equilibrated at 300 K for 5 ns, the time step was set to 2 fs, 
and the SHAKE algorithm was used to constrain bonds involving H. The aC atoms of the 
transmembrane regions were restrained to the initial positions with a 5 kcal/molA2 force 
constant. 
The hydrophobic residues were determined by using the LigPlot 4.4.2. software 
[Wallace et al., 1995]. 
In the determination of the electrostatic interactions, we used the following filters: (1) 
the distance between the acceptor and the donor atoms should be less than 3.2 A or 4 A for 
H-bond and electrostatic interactions, respectively [Fernandez et al., 2004]; (2) and the angle 
formed by the acceptor-H-donor atoms should be more than 90° in all cases. 
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111.2.3. Receptor-based alignment of the BZX analogues 
The binding pocket 3D structure obtained from the refinement procedure was the basis 
of the receptor-based alignment of the 57 BZX analogues. First, the compounds were 
superimposed with the most active compound and the alignment was carried out with 
AutoDock 3.05. During the docking calculations, the same parameters were used as before, 
except that the docking box (40x40x60 grid points) was centred on the ligand, and 50 docking 
calculations were performed. The structures obtained were cluster analysed with 0.5 cluster 
tolerance, using the free energy of binding (AGbind) as descriptor, and the lowest-energy 
structure was selected from the most loaded cluster. After the docking, all receptor - ligand 
complexes were minimized in a multi-step protocol by means of MOE 2005.06, using the 
MMFF94s force field [Halgren [ a , b , c , d ], 1996; Halgren et al., 1996]: (0 the receptor atoms were 
restrained to their initial positions with a force constant of 1000 kcal/molA2 until the gradient 
achieved the value 10; (//) in the second stage, the force constant was decreased to 
100 kcal/molA2 until the gradient was less than 1; and (iii) in the final stage, all receptor 
residues closer than 4.5 A to the ligands were allowed move freely, while the remainder of the 
protein was restrained to its position with a force constant of 100 kcal/molA2. During the 
minimization process, a distance-dependent dielectric constant (er=4) and a 10 A cut-off were 
used for the long-range non-bonding interactions. 
111.2.4. QSAR studies with scoring functions 
The 58 minimized receptor - ligand complexes were further characterized with two 
different scoring functions, that built-in from AutoDock 3.05 (BIND) and the X-Score 1.2 
developed by Wang et al. (2002). BIND consists of five terms: H-bond, van der Waals, 
electrostatic, solvation and ligand deformation; it was calibrated through the use of 30 
protein - ligand complexes. The first version of X-Score was calibrated by means of 200 
protein - ligand complexes, which was later extended to 800. This scoring function also 
includes 5 terms: H-bond, van der Waals, hydrophobic, ligand deformation and the last is the 
regression constant, which implicitly includes the entropy loss during ligand binding. The 
hydrophobic term is calculated in 3 ways: hydrophobic contact potential (HP), hydrophobic 
matching (HM) and hydrophobic surface area (HS); and a fourth could be derived, the 
average (AVE) of the three hydrophobic terms. These 5 scoring functions and the estimated 
AGbind were used in the QSAR characterization of the investigated non-peptide compounds. 
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III.2.5.3D-QSAR calculations 
In the 3D-QSAR calculations, CoMFA (Cramer et al., 1988) with the cross-validated 
r2(q2)-guided region selection (q2-GRS) method (Cho et al., 1995) was utilized, with which 
the orientation-dependent properties of CoMFA calculations could be excluded. First, 
conventional CoMFA calculation with an automated generated box was performed; the initial 
box was divided into 125 equal small boxes and for each small box CoMFA calculations were 
performed with C.3 (+1) atom type, and 1.0 A step size. Only those small boxes were taken 
into consideration in the further calculations in which q 2 reached a special cut-off: 0.1, 0.2, 
0.3,0.4 or 0.5. 
To choose the appropriate parameters and check the statistical significance of the 
models, leave-one-out (LOO) and leave-multiple-out (LMO, 5 groups, 500 runs) 
cross-validation schemes were used. During the PLS calculations, the maximum number of 
components was set to 10, and the minimum sigma value was set to 2 kcal/mol. The final 
non-cross-validated models were built with the number of components obtained from the 
cross-validated calculations. The results were interpreted graphically by field contribution 
maps (stdev*coeff). 
The CoMFA and PLS calculations were performed with the QSAR module of the 
Sybyl 7.1 program package. 
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IV. Results 
IV. 1. Structural properties of peptide OT antagonists 
IV.1.1. Main-chain and side-chain dihedral angle distribution 
In order to identify the preferred main chain dihedral angles of the 8 compounds, 
instead of the conventional Ramachandran plot, the more informative Ramachandran density 
plots were used. The O-T space was divided into 20°x20° boxes, and the number of structures 
in each box was calculated, and divided by 2000 (Figure 3). In Figure 3, only the 02-vP2 
spaces are depicted, because the influence of the second modified amino acid was captured 
only in this region. 
For d(oet)tyr, dcp and dpff, the same Ramachandran space was detected as the most 
preferred region for these peptides. The highest-loaded region was as follows: 
(-80)°<02<(-60°) - (-40°)<xF2<(-20°), and in the 5 highest-loaded regions 24.25%, 25.75% and 
26.20% of the generated structures were obtained for d(oet)tyr, dcp and dpff, respectively. In 
the cases of dtrp and digl, the Ramachandran density plots are very similar to those of the 
flexible Phe analogue-containing peptides. In these cases, the space 
14O°<02<16O° - (-160°)<vP2<(-140) was detected as the most preferred (Figure 3). Here, we 
may note that the second most loaded-region was (-80)°<02<(-60°) - (-40°)<T2<(-20°). In the 
5 greatest-loaded regions, 23.85 and 23.15% of the obtained structures were found. For the 
remaining ligands, very different Ramachandran density plots were obtained. The highest 
population was detected in the spaces 100°<02<120° - (-60°)<4/2<(-40°) and 
8O°<02<1OO°- (-160°)<T2<(-140) for the rrmetcc and rtcc analogues, respectively. More than 
40% of the structures were found in the 5 greatest-loaded regions. For the rigid Phe 
analogue-containing peptide, rate, the most preferred region was 
160°<02<180° - (-60°)<T2<(-40°), and more than 40% of the structures were found in the 5 
highest-loaded regions. 
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Figure 3. Density distributions of the structures in <D2-¥2 space: (a) d(oet)tyr, (b) dcp, (c) digl, (d) dpff, (e) 
dtrp, (f) rate, (g) rrmetcc and (h) rtcc. 
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Besides the main-chain, the preferred side-chain conformations were also determined in the 
series of ligands (Table 4). 
ID Preferred side-chain conformations 
% % % E 
d(oet)tyr 40.00 [g(+)l 18.45 [g(-)] 39.60 [160°] 98.05 
dep 41.50 [g(+)] 21.70 [g(-)] 35.20 [160°] 98.40 
digl 29.35 [g(+)] 28.05 [g(-)] 22.65 [160°] 80.05 
dpff 41.45 [g(+)] 24.20 [g(-)] 32.10 [160°] 97.75 
dtrp 37.50 [g(+)] 23.85 [g(-)] 36.40 [160°] 97.75 
rrmetcc 72.70 [-40°] 27.10 [30°] 0.00 [160°] 99.80 
rtcc 84.75 [-40°] 15.25 [30°] 0.00 [160°] 100.00 
rate 36.25 [+70°] 0.00 [g(-)] 51.40 [160°] 87.65 
Table 4. Preferred side-chain conformation with percentage occurrence. g(+) -
gauche(+) (60°); g(-) - gauche(-) (-60°). From the preferred dihedral angle, ± 10° was 
allowed in the calculation of the distribution. 
For flexible ligands, the preferred orientations were as follows: g(+), g(-) and 160°. 
For rigid tryptophan analogues (rrmetcc and rtcc), the most preferred detected orientation 
was -40° and for rate it was 160°. 
Taking the lowest-energy compounds from the most-loaded Ramachandran region, the 
compounds were superimposed by the main chain heavy atoms of the second residue (Figure 
4). 
Figure 4. The superimposed ligands - d(oet)tyr [red], dep [green], digl 
[black], dpff [blue], dtrp [violet], rrmetcc [orange], rrtcc [cyan] and 
rate [yellow], 
IV.1.2. H-bonds and secondary structure elements 
Three types of H-bonds could be identified for the peptides: main-chain - main-chain, 
main-chain - side-chain and side-chain - side-chain interactions. All three types were 
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determined in the compounds. The criterion of the H-bond was as follows: the distance 
between the acceptor and H atom should be <2.8 A (default value in Sybyl program package), 
and the angle formed by the acceptor, H and donor atom should be >90° (Aakeroy et al., 
1999). 
For the side-chain - side-chain interactions, no significant differences were detected; 
only 8-9% of the 2000 structures was found to be H-bonds. Among these structures the 
Thr4OGl -H-ND2Asn5 and Asn5ODl -H-NEOrn8 type H-bonds were favoured for d(oet)tyr, 
whereas in the remaining compounds the Asn5ODl"H-NE2Gln4 type H-bond was the most 
preferred. 
Three types of main-chain - side-chain H-bond interaction were also detected in all 
compounds: Asn5ODl-HN-NCys6 (16-19%), Gln40(Thr40)-H-ND2Asn5 (5-7%) and 
Asn50-H-ND2Asn5 (5-6%). 
For the main-chain - main-chain interactions, we obtained two types of H-bond, where 
the influence of the second amino acid could be identified. These interactions were as follows: 
Mpa'(0)-Ile3(HN) and Mpa1(0)-Gln4/Thr4(HN) (Table 5). 
Percentage occurrence of 
H-bonds 
Acceptor Mpa ' (O) 
Donor Ile3(HN) GIn4/Thr4(HN) 
d(oet)tyr 9.90 4.65 
dcp 10.00 5.40 
digl 9.75 4.90 
dpff 10.15 5.05 
d t rp 9.40 4.80 
rate 17.20 8.80 
rrmetcc 40.15 11.25 
rtcc 18.75 7.95 
Table 5. Percentage occurrences of H-bonds. 
It is evident that P-turn structures could be evolved in 4 consecutive amino acids if the 
d(Ca/"Ca>i+3) < 7Â, and these structures could be stabilized over If—4 H-bonds [Schlick, 
2002]. Thus, in the evolved If—4 H-bond structures, the occurrence of possible P-turns was 
also investigated. In all cases, the P-turn structures were identified and, with the further 
distance filtration over the 2000 structures, this secondary structure element was identified in 
50% of the structures. 
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IV.2. QSAR studies of non-peptide OT antagonists 
IV.2.1. Relevant 3D model of the hOTR 
After the homology model building and refinement, the 3D hOTR obtained model 
(Figure 5) was tested via the MOE/Protein report module. No significant differences were 
obtained as compared with the values published by Laskowski et al. [1995]. 
Figure 5. Structure of the hOTR after the homology modelling. The Ala318 residue is depicted (ball and stick). 
TM1 - red; TM2 - blue; TM3 - yellow; TM4 - violet; TM5 - orange; TM6 - cyan and TM7 - green; the 
extracellular (EC) loops are coloured dark-green, and the intracellular (IC) loops black. 
IV.2.2. Possible active conformation of the hOTR - BZX complex 
By means of AutoDock 3.05, 500 conformers were generated in the receptor putative 
active site. Using the filtration criteria, the number of structures was decreased to 18, and 
these structures were refined with the aC constrained SA protocol. The 6 structures with 
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lowest energy were selected, and AGbind was calculated by using the built-in scoring function 
of AutoDock 3.05 (Table 6). 
ID AGbj„dii AGbind,f AGb|nd,sA 
A 462.3 -22.9 -25.1 
B 516.1 -23.3 -23.6 
C 525.5 -23.4 -23.7 
D 670.3 -25.1 -24.5 
E 700.9 -24.0 -24.4 
F 795.8 -23.7 -24.0 
Table 6. Predicted free energy of binding in kcal/mol for complexes A, B, C, D, E and F before force field 
minimization (AGbind,i, using a rigid receptor), after force field minimization (AGbind,f) and after the SA protocol, 
using the lowest-energy structure (AGbind,sA)- The AGbind values were calculated by using the built-in scoring 
function of AutoDock 3.05 [Morris et al., 1998]. 
The negative AGbind values indicated that the refinement was successful after the rigid 
docking. For complexes A, C and D, the morpholinone ring of the compound was located 
between the TM6 and TM7 regions, near the superficies of the receptor; these were therefore 
excluded from the further calculations. 
For the remaining structures (complexes B, E and F), the hydrophobic, H-bond and 
electrostatic interaction points were determined (Tables 7 and 8). In the evaluation of the 
electrostatic interaction points, all residues within 4.5 A of the possible anchor point in the 
ligand were taken into consideration. 
Complex 
B 
Complex 
E 
Complex 
F Complex ID Interacting atoms 
d(A—D) 
/A 
a(A -H-D) 
r 
- Leu74 - complex B L 0 3 - V a l 9 3 H 5.28 123.6 
Phe77 Phe77 - L 03—Glyl22 H 5.00 115.8 
Met78 Met78 Met78 L 03—Ser319 HG 5.17 44.6 
Leu81 Leu81 Leu81 + L 04—Glyl22 H 3.46 106.5 
Val88 Val88 Val88 * L 04—Metl23 H 2.80 93.8 
Gln92 - Gln92 L 04—Asn321 HD21 4.45 64.9 
Val93 - - + L 04—Asn321 HD22 3.65 110.9 
Glnl 19 Glnl 19 Glnl 19 L 02—Trp288 H 4.23 75.2 
- - Glyl22 L 02—Trp288 HE1 6.66 34.2 
Met 123 Met 123 Met 123 + L 0 1 - S e r l 2 6 HG 3.83 95.1 
Serl26 Serl26 Serl26 + L Ol—Phe284 H 3.61 94.4 
Thrl27 - Thrl27 L 0 1 - A s n 3 2 5 HD21 4.63 119.2 
Leu129 - - L 0 1 - A s n 3 2 5 HD22 6.20 8.8 
Leu130 Leu130 Leul30 + L H22—Serl26 OG 3.52 151.1 
Met 133 Met 133 Met 133 L H22—Asn325 OD1 4.32 134.9 
Phel85 - - L 0 5 - L e u l 2 9 H 5.00 91.9 
Asp186 - - L 05—Leul30 H 3.56 61.9 
Met276 - - L 0 6 - H i p 8 0 HD1 4.64 133.6 
- - Thr277 L N5—Leu81 H 4.99 124.3 
Ile280 Ile280 Ile280 L 07—Tyr329 H 3.12 73.6 
- - Ala283 complex E + L 04—Glyl22 H 3.81 106.7 
Phe284 Phe284 Phe284 * L 04—Metl23 H 2.99 100.5 
Cys287 Cys287 Cys287 L 04—Asn321 HD21 4.45 64.1 
- - Trp288 L 04—Asn321 HD22 4.45 111.7 
Ala318 Ala318 Ala318 L 02—Thrl27 HG1 4.70 110.5 
Ser319 Ser319 Ser319 L 01—Serl26 HG 4.21 98.0 
Asn321 Asn321 Asn321 + L 0 1 - P h e 2 8 4 H 3.77 97.0 
- - Ser322 L 0 1 - A s n 3 2 5 HD21 4.87 121.5 
Asn325 - - L Ol— Asn325 HD22 4.87 10.8 
Ile328 - - L 05—Asn325 HD21 4.50 91.7 
Tyr329 - Tyr329 L_05—Asn325_HD22 4.50 31.8 
Table 7. Evolved hydrophobic * L H22—Serl26 0 2.72 127.6 
interactions determined for L 06—Hip80 HD1 5.87 127.1 
complexes B, E and F with the L 06—Leu81 H 5.08 112.4 
LIGPLOT software [Wallace et al., L N5—Met78 H 3.64 70.8 
1995]. + L 07—Argl37 H l l 3.59 111.8 
L 0 7 - T h r 2 7 7 HG1 4.71 81.3 
complex F L 03—Gln92 HE21 4.30 62.7 
L 03—Gln92 HE22 4.30 63.6 
L 03—Ser319 HG 3.89 86.9 
L 04—Ser319 HG 4.95 116.0 
L 04—Glnl 19 HE21 3.15 73.1 
L 0 4 - G l n l 19 HE22 3.15 56.2 
L 02—Thrl27 HG1 4.41 83.4 
+ L 0 1 - P h e 2 8 4 H 3.69 104.7 
* L 0 1 - S e r l 2 6 HG 2.88 92.4 
* L H22—Serl26 OG 2.88 146.9 
L H22—Asn325 0D1 4.71 149.9 
L 0 5 - L e u l 3 0 H 3.67 64.9 
L N5—Met78 H 3.69 74.3 
L 07—Met78 H 4.76 124.7 
Table 8. Possible electrostatic interactions in complexes B, E and F. 
d ( A - D ) is the distance between the heavy atoms, and a (A-H-D) is the 
angle formed by the acceptor, H and donor atoms. L denotes the ligand. 
The regular H-bonds meeting the detection criteria are indicated by an 
asterisk and the electrostatic interactions by a plus sign. 
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The locations and the three conformers in the hOTR putative active site are depicted in 
Figure 6. 
Figure 6. (a) Locations of the three conformers (complex B - blue; complex E - red; and complex F - green) in 
the TM regions of the hOTR. For clarity, only TM domains are depicted: TM1 - red; TM2 - blue; TM3 -
yellow; TM4 - purple; TM5 - orange; TM6 - cyan and TM7 - green, (b) Alterations in the structures of the 
three conformers. 
It is well known that, because of the dynamic behaviour of the receptor - ligand 
complexes the predefined anchor points can be changed; we therefore performed MD 
simulations on the three complexes. The time vs. root-mean-square distance (RMSD) is 
depicted in Figure 7. 
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Figure 7. Time vs RMSD plots for complexes B (blue), E (green) and F (red). 
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The average AGbind in the last 1 ns trajectory was calculated by using BIND, taking 
every 50 ps frame into consideration: -22.7±0.5, -23.0±0.3 and -23.3±0.5 kcal/mol, for 
complex B, E and F, respectively. The dynamic hydrophobic and electrostatic interactions 
were also determined in the same time interval (Tables 9 and 10). 
Percentage occurrence 
Complex B Complex E Complex F 
Leu74 0.0 51.2 87.4 
Phe75 0.0 0.0 71.0 
Phe77 17.2 41.2 46.5 
Met78 99.2 95.9 95.5 
Leu81 99.8 95.3 86.1 
Val88 0.0 83 100.0 
Gln92 29.2 100.0 93.9 
Val93 0.0 10.9 5.3 
G l n l l 9 100.0 100.0 95.1 
Glyl22 0.0 0.0 82.1 
Metl23 100.0 100.0 98.7 
Serl26 100.0 100.0 100.0 
Thrl27 99.5 99.1 94.2 
Leu129 92.9 27 11.6 
Leul30 91.7 97.7 99.6 
Metl33 86.6 100.0 99.9 
Argl37 0.0 6.2 0.0 
Phel85 11.6 5.6 0.0 
Aspl86 0.0 32.5 0.0 
Trpl88 21.1 0.0 0.0 
Thr273 0.0 3.7 0.0 
Met276 88.4 96.2 99.9 
Thr277 1.8 1.7 84.7 
Ile280 100.0 100.0 100.0 
Ala283 19.3 50.1 89.0 
Phe284 100.0 100.0 100.0 
Cys287 73.4 67.9 99.7 
Trp288 100.0 99.8 100.0 
Phe291 17.1 0.0 0.0 
Met315 44.5 0.0 0.0 
Ala318 100.0 100.0 98.2 
Ser319 62.2 100.0 99.4 
Leu320 0.0 0.0 1.5 
Asn321 100.0 100.0 99.9 
Asn325 38.3 0.0 3.5 
Ile328 87.2 0.0 0.0 
Tyr329 54.7 0.0 99.7 
Table 9. Percentage occurrences of hydrophobic contact residues for complexes B, E and F in the last 1 ns 
trajectory. The bold percentage values indicate those residues which were identified in the 3 static complexes 
(see Table 7). 
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Complex ID d(A-D)/A a(A-H-D)/° Percentage occurrence of interaction 
mean±SD mean±SD H-bond electro E 
Complex B * L 0 3 - Ser319_HG 3.24±0.48 98.2±33.0 45.0 14.9 59.9 
+ L O l - Serl26_HG 4.12±0.18 89.4±19.6 0.0 15.8 15.8 
+ L O l - Phe284_H 4.03±0.21 88.9±12.5 0.0 21.7 21.7 
Complex E + L 0 4 - Glyl22_H 3.91±0.17 102.7±6.8 0.0 71.3 71.3 
* L 0 4 - Metl23_H 3.17±0.16 99.1±12.6 44.8 31.0 75.8 
+ L O l - Phe284_H 3.79±0.20 90.2±11.6 0.1 43.4 43.5 
* L H22 -Se r l26_0 2.87±0.12 122.4±12.8 99.1 0.7 99.8 
* L 0 7 - Argl37_Hl 1 3.68±0.29 114.0±15.6 5.1 75.9 81.0 
Complex F * L 0 4 - Glnl 1 9 H E 2 2 3.42±0.30 145.3±13.5 24.8 70.5 95.3 
+ L 0 2 - Thrl27_HGl 4.22±0.23 99.3±11.9 0.0 12.5 12.5 
+ L O T - Serl26_HG 3.87±0.32 98.9±23.7 0.2 54.1 54.3 
+ L _N5- Met78_H 3.47±0.15 79.0±9.9 0.9 13.8 14.7 
Table 10. Calculated electrostatic interactions in the dynamic complexes B, E and F. d ( A - D ) is the distance between 
the two heavy atoms, a ( A - H - D ) is the angle formed by the acceptor, H and donor atoms. L denotes the ligand. The 
last three columns list the percentage occurrence of the H-bond, only electrostatic (electro) and the total electrostatic 
(E) interactions. The regular H-bonds meeting the detection criteria are indicated by an asterisk and the electrostatic 
interactions by a plus sign. 
IV.2.3. AGbind estimation and active site support 
The molecular docking and MD calculations revealed a possible active conformation 
formed between the hOTR and the most active BZX compounds: complex E. To support this 
result, and determine a simple mathematical equation with which estimation of a newly 
synthetized compound is possible, further docking and AGbind calculations were performed. 
With the receptor-based alignment of 58 BZX compounds, AGbind was estimated by means of 
5 scoring functions: BIND, HP, HM, HS and AVE (Annex/Table Al). It is clear that the 
calculated AGbind is <0 kcal/mol for each compound (Figure 8). 
X-Score - HS AutoDock 3.05 built-in 
measured pKj measured pKj 
Figure 8. Plots of the estimated AGbind v s measured pKj using various scoring functions 
including all 58 compounds. The determined outliers (compound 44 and 45) are depicted with a 
box. 
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Linear regression with cross-validation was performed to determine the statistical 
significance of the models. Linear regression was performed first, including all 58 
compounds; the parameters obtained are listed in Table 11. 
Scoring 
function 
Cross-validated 
model parameters 
Non-cross-validated 
model parameters 
q2 SDEP r2 s F(l,56) 
HP 0.255 0.722 0.320 0.690 26.313 
HM 0.235 0.732 0.307 0.696 24.847 
HS 0.301 0.699 0.358 0.670 31.201 
AVE 0.266 0.717 0.331 0.684 27.691 
BIND 0.322 0.689 0.371 0.663 33.079 
Table 11. The parameters of the cross-validated and non-cross-validated models, 
obtained by using different scoring functions, all 58 compounds were included in the 
calculations.q2 - cross-validated r2, SDEP - standard error of prediction, s - standard 
error of estimate, r2 - conventional r2, F - Fisher (1,56) value. 
We investigated the influence of those compounds, which contain bulky, rigid 
derivative at the position of the amide group after the benzofuran ring: compounds 14, 15,16, 
19, 20, 21, 22, 30, 43, 44, 45, 46, 50, 51, 57 and 58 (Table 12, 13 and 14). (The exact 
explanation, confirmed with more data, of the exclusion of these compounds can be found in 
the article: B. Jójárt, Á. Márki: Receptor-based QSAR studies of non peptide human oxytocin 
receptor antagonists. Journal of Molecular Graphics and Modelling Accepted for publication 
(Appendix IV.)) 
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Scoring Cross-validated Non-cross-validated model parameters 
function model parameters 
q2 SDEP r
2 s F(l,40) linear model 
HP 0.635 0.547 0.667 0.522 80.009 pKj= -0.380-0.637* AGbbld(HP) 
HM 0.636 0.546 0.671 0.519 81.404 p K r -0.669-0.725 *AGbind(HM) 
HS 0.679 0.513 0.706 0.491 96.069 pKj=-l.724-0.765 *AGbmd(HS) 
AVE 0.658 0.529 0.688 0.505 88.242 pKj= -0.990-0.714xAGblnd( AVE) 
BIND 0.655 0.531 0.684 0.509 86.675 pKj= 1.642-0.306* AGbind(BIND) 
Table 12. The parameters of the cross-validated and non-cross-validated models, obtained by using different scoring 
functions, without rigid derivatives containing compounds (14, 15, 16,19, 20, 21, 22, 30, 43, 44, 45, 46, 50, 51, 57 and 58). 
q2 - cross-validated r2, SDEP - standard error of prediction, s - standard error of estimate, r2 - conventional r2, F - Fisher 
(1,40) value. 
Scoring Cross-validated Non-cross-validated model parameters 
function model parameters 
q^ SDEP r^  s F(l,32) linear model r2pred 
HP 0.616 0.562 0.657 0.531 61.371 pK.^-0.017-0.607* AGbind(HP) 0.76 
HM 0.613 0.563 0.657 0.531 61.211 pKi=-0.240-0.685><AGbi„d(HM) 0.80 
HS 0.649 0.537 0.686 0.508 69.760 pKi=-1.307-0.729><AGbind(HS) 0.85 
AVE 0.635 0.548 0.673 0.518 65.998 pKj=-0.582-0.678*AGbind(AVE) 0.81 
BIND 0.629 0.552 0.668 0.522 64.450 pK,= 1.971-0.289*AGbind(BIND) 0.83 
Table 13. The parameters of the cross-validated and non-cross-validated models, obtained by using different scoring functions for the training 
set, without rigid derivatives containing compounds (14, 15, 16, 19, 20, 21, 22, 30, 43, 44, 45, 46 and 50). 
q2 - cross-val ¡dated r2, SDEP - standard error of prediction, s -s tandard error of estimate, r2 - conventional r2, F - Fisher (1,32) value, 
r"pred - predictive r2 for the test set. 
to - j 
ID 
Measured 
pK, 
Predicted pK| 
HP HM HS AVE BIND 
47 6.1 6.43 6.61 6.24 6.44 6.45 
48 7.2 7.17 7.10 7.13 7.15 7.29 
49 6.5 7.05 6.95 6.89 6.98 7.16 
52 7.6 7.99 7.85 7.78 7.90 7.74 
53 8.2 7.53 7.51 7.47 7.52 7.72 
54 8.6 7.92 7.93 7.86 7.93 7.96 
55 8.7 8.01 8.10 8.18 8.12 8.04 
56 8.0 8.11 8.16 7.98 8.11 8.17 
Table 14. The predicted pKj values obtained by using different scoring functions. In the 
and test sets the rigid derivatives containing compounds were not included (compounds 
51, 57 and 58). 
IV.2.4. Predictive QSAR models of non-peptide OT antagonists using CoMFA with 
q2-GRS 
To improve the biological activity prediction of newly synthetized compounds, we 
performed 3D-QSAR calculations. To determine the actually important regions around the 
molecules, and exclude the influence of the orientation, we determined the region by using the 
q2-GRS method developed by Cho et al. [1995]. 
With the protein-based alignment of the 58 compounds (Figure 9), the conventional 
CoMFA calculation resulted in the following parameters: q2=0.723, SDEP=0.452 and n=4. 
a 
Figure 9. Receptor-based alignment of the training (a) 
and test (b) set. 
The parameters of the cross-validated and non-cross-validated models of the whole 
dataset and of the training set are listed in Tables 15 and 16, respectively. 
28 
Model q2 Number Cross-validated Non-cross-validated parameters 
cut-off of boxes parameters 
q2 SDEP n s r
2 F Norm, coeff. (frac.) 
ste ele 
conventional - 125 0.723 0.452 4 0.244 0.920 151.872a 1.669 (0.452) 2.027 (0.548) 
model A 0.1 34 0.711 0.462 4 0.249 0.916 144.2703 1.614(0.443) 2.030 (0.557) 
model B 0.2 31 0.709 0.464 4 0.248 0.917 146.3283 1.641 (0.447) 2.029 (0.553) 
model C 0.3 26 0.706 0.466 4 0.249 0.916 144.6653 1.644 (0.4489 2.022 (0.552) 
model D 0.4 23 0.710 0.464 6 0.177 0.959 200.803b 2.550 (0.461) 2.636 (0.539) 
model E 0.5 17 0.706 0.476 6 0.183 0.957 187.184b 2.214(0.458) 2.624 (0.542) 
Table 15. The parameters of the various CoMFA calculations on 58 compounds, q -cross-validated r , SDEP - standard error of prediction, 
n - optimum number of components, s - standard error of estimate, r2 - conventional r2, F - Fisher value ["(4,53), b(6,51)]. 
Model q2 Cross-validated Non-cross-validated parameters 
cut-off parameters 
q2 SDEP n r
2 s F(4,41) Norm, coeff. (frac.) 
ste ele 
r2 1 pred 
Model A 0.1 0.649 0.518 4 0.247 0.920 118.567 1.657(0.436) 2.143 (0.564) 0.90 
Model B 0.2 0.645 0.521 4 0.245 0.921 119.944 1.667 (0.436) 2.160(0.564) 0.91 
Model C 0.3 0.641 0.524 4 0.247 0.920 118.625 1.670 (0.436) 2.160 (0.564) 0.90 
Model D 0.4 0.647 0.519 4 0.246 0.921 118.860 1.664 (0.431) 2.192 (0.569) 0.89 
Model E 0.5 0.645 0.521 4 0.251 0.918 114.656 1.632 (0.427) 2.189 (0.573) 0.89 
Table 16. The parameters of the various CoMFA calculations, using the training set (46 compounds), q2 - cross-validated r2, SDEP - standard error 
of prediction, n - optimum number of components, s - standard error of estimate, r2 - conventional r2, F(4,41) - Fisher value, r2pred - predictive r2 on 
test set. 
M vo 
The biological activity of the test set was also investigated. The regression coefficients 
resulted in a value of 0.9 for each model (Tables 16 and 17). 
ID 
Measured Predicted pKj 
pKi Model A Model B Model C Model D Model E 
47 6.1 6.50 6.49 6.50 6.51 6.49 
48 7.2 6.78 6.77 6.76 6.72 6.79 
49 6.5 6.74 6.74 6.74 6.78 6.79 
50 6.9 6.93 7.02 7.00 7.08 7.14 
51 6.7 6.95 6.87 6.90 6.82 6.87 
52 7.6 8.19 8.19 8.20 8.19 8.19 
53 8.2 8.25 8.23 8.21 8.21 8.20 
54 8.6 8.54 8.53 8.58 8.58 8.63 
55 8.7 8.69 8.69 8.72 8.72 8.62 
56 8.0 8.00 8.00 8.00 8.00 8.00 
57 8.0 7.85 7.86 7.84 7.83 7.75 
58 7.2 7.29 7.29 7.28 7.30 7.26 
Table 17. The predicted biological activities for the test set, using various models. 
To test the predictive power of the model obtained by using 58 compounds and a 0.5 
q2 cut-off, when the model is extended to other compounds, LMO cross-validation was 
performed 500 times, with 5 groups (Table 18). 
Model E MeaniSD Min Max 
q2 0.695±0.034 0.589 0.766 
SDEP 0.477±0.0326 0.424 0.562 
n 4.74±0.88 2 7 
Table 18. The results of LMO cross -validation (500x) using 5 groups for 
model E. q2 - cross-validated r2, SDEP - standard error of prediction, 
n - optimum number of components. 
The field contribution maps obtained from the non-cross-validated model E are 
depicted in Figures 10 and 11. 
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Figure 10. Contour plot of steric field contribution maps (stdevxcoeff). Larger pK, 
values correlated with more bulk near green and less bulk near yellow. Compound 37 
( p K j = 8 . 4 ) is depicted as reference molecule. 
Figure 11. Contour plot of electrostatic field contribution maps (stdevxcoeff). Larger pKj 
values correlated with more positive charge near blue, and with more negative charge 
near red. The most active compound ( 3 5 , p K j = 9 . 3 ) is depicted as reference molecule. 
P %, n 
V. Discussion 
V.l. Structural properties of modified OT peptide antagonists 
By means of restrained simulated annealing, the conformational space of 8 peptide OT 
antagonists was explored and analysed. In the calculations, we used a non-receptor-based 
method, because the guinea pig OT receptor sequence is not yet available. The influence of 
the second modified amino acid was captured in the main- and side-chain dihedral angle 
distribution, as in the evolved H-bond interaction types and secondary structure elements. 
Analogues with good biological activities (Kj<100nM) share very similar structural 
properties, while the conformationally restricted amino acid-containing peptides comprise the 
other group. The difference in the dihedral angle is clearly presented in Figure 4. Analogues 
with with low Kj (<100 nM) occupy the same location, while the orientation of the second 
amino acid differs for rrmetcc, rtcc and rate. The same case could be evolved in the ligand 
binding; the ligand could not occupy the receptor cavity exactly according to the anchor 
points. 
V.2. Quantitative structure-activity relationships for non-peptide OT antagonists 
By means of homology modelling, the 3D structure of the hOTR was constructed. In 
consequence of the high variability of the N- and C-terminal regions of the protein, the 
modelling of these parts is very difficult, and therefore only truncated terminals were included 
in the calculations. In the literature, there are no data which indicate that the N- and 
C-terminals are included in the non-peptide antagonists binding; accordingly, the deletion of 
residues has no influence on our results. As no differences were obtained from the values 
determined by Laskowksi et al. (interatomic distances, angles and dihedral angles), the model 
is suitable as a good starting structure (inactive form) to model receptor - ligand interactions. 
By means of molecular docking calculations, filtration criteria and refinements on the 
complexes, we finally obtained 3 possible active conformations. The basis of the elimination 
of complexes A, C and D is that the morpholinone moiety of the molecule could interact with 
membrane lipids, which is irrelevant. By evaluation of the structural elements of the 
A I A 
remaining complexes, B, E and F, the most important contact residue, Ala , was identified 
[Hawtin et al., 2005]. This result confirms the possible active conformation. Besides the 
hydrophobic interaction (Table 7), the other possible interaction type, electrostatic, was also 
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determined (Table 8). We observed no essential differences between the hydrophobic and 
electrostatic interactions, though differences were manifested in the location and orientation 
of the ligand in the receptor cavity (Figure 6). The alignment of the benzofuran moiety of the 
compound is maximum. The BZX part in complexes B and E is also superimposed. The 
differences between these structures are the position of the amide group and the fact that the 
morpholinone ring is folded back. In complex F, the amide group is positioned in another 
orientation than in complex E; it therefore overlaps with the amide group of complex B. The 
orientation of the BZX ring in complex F is different from that in complexes B or E; it is 
rotated by 180° relative to the ring in the other two complexes. These results allow the 
conclusion that a stable receptor - ligand complex could be evolved through hydrophobic and 
electrostatic interactions. The locations of the ligands in the TM regions are in good 
agreement with the fact that low molecular weight ligands bind to the hydrophobic part of the 
GPCRs [Gether et al., 1998]. To decide which complex is most likely, we performed MD 
simulations to determine the dynamic anchor points in the complexes. The plots of RMSD vs. 
time allowed the finding that a stable state could be evolved in the last 1 ns of the trajectory, 
and therefore only this part of the trajectory was further analysed. The average AGbind and the 
occurrence of hydrophobic and electrostatic interaction points were determined. The AGbind 
values did not change significantly as compared with the static complex. In the case of the 
«j 1 q 
hydrophobic interactions, the Ala residue was determined in each complex. Although there 
was a minor alteration in the occurrence of Ala 3 1 8 (98.2%) in the case of complex F, the 
structures did ot follow each other, and therefore this complex was not excluded. The 
electrostatic profiles of complexes B and F were complete rearranged. After the SA in the 
case of complex B, 6 interactions met our H-bond or electrostatic criteria (L_04-Gly 1 2 2_H, 
L_04—Met123_H, L_04-Asn 3 2 1_HD22, L_01-Ser 1 2 6_HG, L_01-Phe 2 8 4_H and 
L_H22—Ser126_OG). After the MD simulation, only 3 cases met the criteria: 
L_01—Ser126_HG, L_01-Phe 2 8 4_H, and a new interaction point, L_03 • Ser3 1 9_HG. For 
L_01-Ser 1 2 6_HG, L_01-Phe 2 8 4_H; the percentage occurrence was only 15.8% and 21.7%, 
respectively. For L_03-Ser 3 1 9_HG, a H-bond appeared in 50% of the structures. In complex 
F, the electrostatic profile was changed to be very similar to that for complex B. After the SA, 
three interactions (L_01-Phe 2 8 4_H, L_01-Ser 1 2 6_HG and L_H22-Ser , 2 6_OG) met the 
criteria. After the dynamics simulation, only L_01-Ser 1 2 6_HG was kept; the other three 
electrostatic interactions emerged in the dynamics simulation. We obtained H-bond 
interactions only in L_04—Gin119_HE22. For complex E, a very different electrostatic profile 
was observed. After the SA, 5 interactions were determined to be electrostatic interactions 
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(L_04-Gly m _H, L_04-Met 1 2 3_H, L_01-Phe 2 8 4_H, L_H22-Ser 1 2 6_0 and 
L_07—Arg137_Hl 1). During the MD simulation, these anchor points remained stable. This 
indicated that a more stable complex could occur for complex E as compared with B and F, as 
a result of hydrophobic and electrostatic interactions. The former statement that ligands bind 
in the hydrophobic core of the TM domains is still in good agreement with our results, 
because the interaction sites (about 90-100% hydrophobic) are located in the TM domains of 
thehOTR. 
The final conclusion of these results is that we could determine the most likely active 
complex formed between hOTR and the most active BZX compound. This could be supported 
in two ways. A site-directed mutagenesis study should be performed for the residues Gly 1 2 2 
and Arg 1 3 7. Arg 1 3 7 was determined only for complex E as anchor point, for the G , 2 2 F point 
mutation no H-bond could be evolved due to steric inhibition. The other method is further 
computational simulations, using scoring functions and 3D-QSAR methods. 
All 3D-QSAR methods are based on the assumption that changes in the binding 
affinities of the compounds are related with the changes in the molecular interaction field 
(MIF, Goodford, 1985) generated in the active conformation of the ligands. The crucial point 
of these calculations is the active conformation, but this can be solved very easy, when the 
alignment is based on the target molecule (receptor, enzyme or DNA). Hence, we performed 
docking calculations for the 58 BZX analogues, and the initial receptor model was taken from 
complex E. By using cluster analysis, we determined the most likely docked conformation 
and the evolved receptor - ligand complexes were characterized via different scoring 
functions (Table Al). 
Linear regression using the AGbmd as sole descriptor including all 58 componds, 
resulted in poor predictive ability, indicated by low q 2 and r 2 values of the models (Table 11). 
On removal of the rigid, bulky substituent containing compounds from the dataset, the 
prediction ability (q2(HS)=0.679) and the goodness of fit (r2(HS)=0.706) increased 
significantly (Table 12). To test the predictive power of the models the linear regressions 
were performed on the training set and the obtained models were tested on the test set. These 
calculations were performed without rigid derivative containing compounds. We obtained 
acceptable r 2 p r ed values (~0.8) in each case (Table 13). Based on these results we can conclude 
that the prediction ability of these scoring functions is poor if there is a rigid derivative at the 
position of the amide group and has a good predictive power in pKj range 6.0-7.5. 
Accordingly, we suggest that the simple linear models could be useful to predict the 
biological activity of compounds without rigid derivatives and with low biological activity. 
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To improve the biological activity prediction, and to consider the shape properties of 
the investigated compounds, 3D-QSAR studies using CoMFA were performed. In order to 
establish which regions are related with the biological activity, the regions were determined 
via the q2-GRS method developed by Cho et al. [1995]. The conventional CoMFA 
calculation, resulted in a 3D model with good predictive ability (q2=0.723). In the q2-GRS 
calculation, we used various q 2 cut-offs: 0.1, 0.2, 0.3, 0.4 and 0.5. The cross-validated and 
non-cross-validated model parameters did not change significantly (Table 15). These results 
allow the conclusion that the regions which are unrelated to the biological activity were 
excluded successfully, and we could extract the maximum amount of chemical information 
from the dataset. It is a well-known fact that a high q 2 does not guarantee good predictive 
ability for external datasets [Kubinyi et al., 1998; Novellino et al., 1995]. To confirm the 
predictive ability of our models, the CoMFA calculations were performed again for the 
training set, and tested on the test set (Tables 16 and 17). r 2 p r ed resulted in a value of 0.90 for 
each model, and this supported the receptor-based alignment of the molecules, and the 
possible active conformation. The predictive power of the models indicates that compounds 
containing rigid derivatives have not been proved to be outliers and the non-cross-validated 
model could be used in biological activity prediction. 
In the selection of the test set we have to pay attention that the selected activities (6.1-
8.7) must cover the range of activities (6.1-9.3), and the structures were selected randomly. A 
possible explanation for the good predictive power is that the chemical variability of the 
training set explains the chemical variability of the test set. Accordingly, we performed LMO 
cross-validation for the whole dataset, where the software selects the test sets randomly. The 
LMO cross-validation was performed for 500 times with 5 groups, which means that the 
model was built by using 80% of the available data (46 compounds) and the model obtained 
was tested on 12 compounds (Table 18). Accordingly, the partition of the data was same as 
used before. Among the 500 LMO cross validation runs, there were 6 calculations in which q 
was higher than 0.7, and 6 in which the q 2 was lower than 0.6. The results confirmed that the 
model is likely to be of certain predictive power when extended to other ligands. 
The important regions in the ligand are (Figures 10 and 11): (1) the bulky substituent 
nearby the CF3 moiety; (2) the negative charge on the benzofuran ring at the position of the O 
atom and at the position of the amide O; and (3) the positive charge at the position of the 
amide H. The steric unfavourable regions are the followings: bulky substituent near the furan 
ring, the amide group and nearby the N atom in the pyrimidin ring. While the linear model of 
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the scoring function could not deal with the substituent near the amide group, with the 
3D-QSAR model this part of the molecule could be taken into consideration exactly. 
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VI. Summary and Outlook 
In the present work, we made an attempt to explore the structure-activity relationships 
in the field of peptide and non-peptide OT antagonists. 
By means of conformational sampling, we developed a simple model with which 
peptide compounds with low biological activity could be excluded from the series of potent 
OT antagonists. Here, we note that the results can be very different from the bioactive 
conformations of these analogues when the non-receptor-based conformations are used in the 
comparative study, but the major aim of the study was the determination of the influence of 
the second amino acid, which was successfully achieved. 
With the aid of molecular docking and MD calculations and energetically and 
structurally criterias, we could identify a probable active conformation formed between the 
human OT receptor and the most active compound. The most important anchor point in the 
receptor - ligand interaction, Ala 3 1 8, was identified, which supports the most likely 
conformation. Further quantitative structure-activity relationship calculations were applied. 
Using scoring functions, a simple linear model was developed, with which estimation of new 
compounds are easy. This model could be used when no rigid bulky substituent is present at 
the location of the amide group, and primarily when pKi<7.5. By means of CoMFA studies 
with the q2-GRS method, this disadvantage of the simple linear model was excluded, and the 
good predictive ability of the various models confirmed the receptor-based alignment of the 
BZX derivatives. 
The above results could be supported via site-directed mutagenesis studies. In the first 
step, the point mutation will be performed theoretically. In the wild-type and point-mutated 
receptor, the most active compound will be docked at least 100 times, and the calculated 
average AGbind will be compared. Where significant differences are obtained, the residues 
could be subjected to mutagenesis study. 
Furthermore, the variable region of the most active compound could be used in 
database (NCI) searching, to identify new, potent OT antagonists. 
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X. Annex 
ID pK, HP HM HS AVE BIND ID pK; HP HM HS AVE BIND 
1 6.90 -10.97 -10.24 -11.08 -10.76 -16.53 30 7.60 -12.25 -11.48 -12.32 -12.02 -21.56 
2 6.80 -11.05 -10.34 -11.08 -10.82 -16.86 31 7.60 -12.49 -11.35 -12.00 -11.95 -20.35 
3 6.70 -10.82 -10.01 -10.65 -10.49 -15.42 32 8.70 -13.57 -12.26 -13.00 -12.94 -21.18 
4 6.70 -10.83 -9.81 -10.71 -10.45 -15.89 33 8.20 -14.36 -13.39 -13.71 -13.82 -22.27 
5 6.10 -10.50 -9.83 -10.54 -10.29 -15.33 34 8.90 -13.33 -12.21 -12.86 -12.80 -21.94 
5 6.90 -10.99 -10.19 -10.76 -10.65 -16.16 35 9.30 -14.05 -12.58 -13.50 -13.37 -23.02 
6 6.60 -10.80 -10.00 -10.65 -10.48 -15.21 36 9.00 -14.64 -13.79 -14.14 -14.19 -23.20 
7 6.40 -10.75 -9.67 -10.64 -10.35 -15.26 37 8.40 -13.24 -12.02 -12.88 -12.71 -21.05 
9 6.90 -11.14 -10.35 -11.28 -10.93 -16.12 38 8.10 -13.57 -12.17 -13.01 -12.92 -21.39 
10 6.10 -11.06 -10.18 -10.97 -10.73 -16.13 39 8.50 -13.38 -12.24 -12.74 -12.79 -21.03 
11 7.40 -11.80 -10.82 -11.39 -11.33 -18.10 40 7.00 -13.52 -12.24 -12.78 -12.84 -20.45 
12 6.40 -12.02 -10.87 -11.78 -11.56 -18.04 41 7.30 -13.65 -12.04 -13.05 -12.92 -21.95 
13 6.80 -12.02 -10.72 -11.51 -11.42 -19.25 42 7.10 -13.42 -12.00 -12.89 -12.77 -21.60 
14 7.70 -12.24 -11.39 -11.83 -11.82 -18.64 43 7.60 -14.20 -12.70 -13.59 -13.49 -23.13 
15 6.80 -12.60 -11.57 -12.48 -12.22 -20.03 44 6.10 -14.23 -13.05 -13.67 -13.65 -22.94 
16 8.00 -12.36 -11.33 -12.09 -11.93 -19.79 45 6.10 -14.72 -13.56 -13.82 -14.03 -22.37 
17 6.40 -11.62 -10.80 -11.24 -11.22 -18.59 46 8.00 -14.29 -12.85 -13.68 -13.61 -21.95 
18 7.40 -11.89 -10.48 -11.88 -11.42 -17.67 47 6.10 -10.63 -10.00 -10.43 -10.35 -15.50 
19 7.20 -12.58 -11.46 -12.44 -12.16 -18.88 48 7.20 -11.84 -10.72 -11.66 -11.41 -18.40 
20 7.10 -12.54 -11.40 -12.21 -12.05 -20.20 49 6.50 -11.63 -10.49 -11.33 -11.15 -17.97 
21 7.10 -12.44 -11.44 -12.40 -12.09 -19.86 50 6.90 -12.11 -11.28 -11.73 -11.71 -19.10 
22 7.20 -12.28 -11.02 -12.02 -11.77 -20.04 51 6.70 -12.28 -11.18 -11.74 -11.73 -18.94 
23 7.20 -11.73 -10.79 -11.73 -11.42 -17.19 52 7.60 -13.19 -11.81 -12.55 -12.52 -19.97 
24 7.80 -12.26 -11.23 -12.17 -11.88 -18.44 53 8.20 -12.43 -11.31 -12.13 -11.95 -19.90 
25 7.60 -12.71 -11.27 -12.49 -12.16 -20.04 54 8.60 -13.08 -11.92 -12.66 -12.55 -20.73 
26 8.20 -13.01 -11.58 -12.63 -12.41 -20.02 55 8.70 -13.22 -12.18 -13.09 -12.83 -21.00 
27 8.50 -12.59 -11.47 -12.29 -12.12 -20.42 56 8.00 -13.38 -12.26 -12.82 -12.82 -21.46 
28 7.80 -13.04 -12.13 -13.03 -12.73 -21.01 57 8.00 -13.94 -12.51 -13.41 -13.29 -22.08 
29 8.40 -12.99 -11.80 -12.66 -12.48 -21.16 58 7.20 -14.36 -13.07 -13.59 -13.67 -22.46 
Table Al . The predicted AGbmd in kcal/mol, by using different scoring functions: BIND - AutoDock 3.05; HP -
hydrophobic contact potential; HM - hydrophobic matching; HS - hydrophobic surface; AVE - mean of HP, HM, 
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